RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Skin Channel

subscribe to Skin newsletter
Latest Research : Cancer : Skin

   EMAIL   |   PRINT
Vaccine being researched for prevention of melanoma

Nov 12, 2004 - 1:07:00 PM

[RxPG] A recent clinical trial of the NY-ESO1/ISCOMATRIXTM vaccine conducted by the Cancer Vaccine Collaborative group at The Austin Health in Melbourne, Australia, has shown that the vaccine successfully induces a comprehensive immune response and suggests that the vaccine may prevent or delay melanoma recurrence in treated patients.

A team of researchers, including lead authors Ian D. Davis, Weisan Chen, and Jonathan Cebon, published the study in the July 20, 2004, issue of the Proceedings of the National Academy of Sciences of the United States of America. The vaccine, which was composed of the cancer-testis antigen NY-ESO-1 and ISCOMATRIXTM (an adjuvant that enhances the immune system response to the antigen), was administered to cancer patients after surgical removal of their tumors. It was observed that out of the 19 patients who received the vaccine, most with melanoma, 14 were cancer-free two years later.

This phase I clinical trial received much press attention, garnering coverage in several prestigious media outlets including leading Australian newspapers, The Age and the Sydney Morning Herald, the UK’s The London Times, and in the news section of Nature. A larger Phase II clinical trial that will specifically test for the vaccine’s ability to prevent or delay recurrence is now under development.

Publication: Cancer Research Institute
On the web: Free Abstract of the Article (Full Article by Subscription Only): 

Advertise in this space for $10 per month. Contact us today.

Related Skin News
High dietary phosphate may promote skin cancer
Compounds extracted from vegetables help to inhibit melanoma
MicroRNA responsible for aggressiveness of metastatic melanoma cell lines
A novel designer molecule to fight malignant melanoma
Polyomavirus strongly associated with Merkel cell carcinoma
Behaviour increases risk of skin cancer in Americans
Gender linked to development of skin cancer
Marathon runners could face risk of skin cancer
Listening to the sound of skin cancer
Malignant melanoma cells secrete a potent embryonic growth factor

Subscribe to Skin Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)